Socuron® (Rocuronium Bromide Injection)
An aminosteroid non-depolarizing neuromuscular blocking agent designed for rapid sequence intubation and balanced anesthesia. Fast-acting, intermediate duration, fully reversible.
Engineered for predictable neuromuscular blockade in diverse surgical and critical care settings.
Intubating conditions achieved within 60–90 seconds at standard doses (0.6 mg/kg). Comparable onset to succinylcholine at higher doses (1.0–1.2 mg/kg), suitable for rapid sequence intubation (RSI).
Clinical duration of 30–60 minutes depending on dose, offering predictable recovery profiles ideal for most surgical procedures of moderate length.
Can be reversed with neostigmine (acetylcholinesterase inhibitor) or rapidly and profoundly reversed with sugammadex (selective relaxant binding agent).
Minimal histamine release at clinical doses. Stable cardiovascular profile with no significant effects on heart rate or blood pressure in most patients.
Intermediate-acting aminosteroid with minimal cumulative effect on repeated dosing. Suitable for maintenance via intermittent bolus or continuous infusion.
Indicated for facilitating endotracheal intubation, providing skeletal muscle relaxation during surgery, and as part of RSI protocols in emergency and ICU settings.
Complete product specification and packaging information.
| Product Specification | |
|---|---|
| Brand Name | Socuron® |
| Generic Name | Rocuronium Bromide Injection |
| Drug Class | Non-depolarizing neuromuscular blocking agent (aminosteroid) |
| Active Ingredient | Rocuronium Bromide |
| Strength | 10 mg/mL |
| Fill Volume | 5 mL per vial (50 mg/vial) |
| Dosage Form | Injectable solution (intravenous) |
| Packaging | Type I borosilicate glass vial |
| Storage | Store at 2–8°C (refrigerated). Do not freeze. Protect from light. |
| Shelf Life | 36 months (refer to label for exact expiry) |
| Route of Administration | Intravenous (IV) bolus or infusion |
Socuron® (rocuronium bromide) is a non-depolarizing neuromuscular blocking agent of the aminosteroid class. It acts as a competitive antagonist at the nicotinic acetylcholine receptor (nAChR) at the neuromuscular junction, preventing acetylcholine from binding and thereby inhibiting neuromuscular transmission.
Unlike depolarizing agents (e.g., succinylcholine), rocuronium does not cause initial muscle fasciculations and produces a more controlled, predictable blockade.
For intravenous use only. Dosage should be individualized based on patient factors and neuromuscular monitoring.
Intubating conditions in ~60–90 seconds with clinical duration of ~30–40 minutes. For routine surgical intubation.
Excellent intubating conditions within 45–60 seconds. Extended duration (~60–90 min). For emergency settings.
Intermittent bolus when TOF returns to ~25% of control. May also be given as continuous infusion at 8–12 mcg/kg/min.
For prolonged mechanical ventilation. Titrate using quantitative neuromuscular monitoring (TOF ≤ 2 twitches).
Click to view full-size advertisement pages.
Request complimentary samples for clinical evaluation and formulary assessment. Provide your hospital data and clinical rationale — we'll respond within 3 business days.
Request Sample →